Literature DB >> 26309843

Quantitation of mitral regurgitation after percutaneous MitraClip repair: comparison of Doppler echocardiography and cardiac magnetic resonance imaging.

Christian Hamilton-Craig1, Wendy Strugnell1, Niranjan Gaikwad1, Matthew Ischenko1, Vicki Speranza1, Jonathan Chan1, Johanne Neill1, David Platts1, Gregory M Scalia1, Darryl J Burstow1, Darren L Walters1.   

Abstract

OBJECTIVE: Percutaneous valve intervention for severe mitral regurgitation (MR) using the MitraClip is a novel technology. Quantitative assessment of residual MR by transthoracic echocardiography (TTE) is challenging, with multiple eccentric jets and artifact from the clips. Cardiovascular magnetic resonance (CMR) is the reference standard for left and right ventricular volumetric assessment. CMR phase-contrast flow imaging has superior reproducibility for quantitation of MR compared to echocardiography. The objective of this study was to establish the feasibility and reproducibility of CMR in quantitating residual MR after MitraClip insertion in a prospective study.
METHODS: Twenty-five patients underwent successful MitraClip insertion. Nine were excluded due to non-magnetic resonance imaging (MRI) compatible implants or arrhythmia, leaving 16 who underwent a comprehensive CMR examination at 1.5 T (Siemens Aera) with multiplanar steady state free precession (SSFP) cine imaging (cine CMR), and phase-contrast flow acquisitions (flow CMR) at the mitral annulus atrial to the MitraClip, and the proximal aorta. Same-day echocardiography was performed with two-dimensional (2D) visualization and Doppler. CMR and echocardiographic data were independently and blindly analyzed by expert readers. Inter-rater comparison was made by concordance correlation coefficient (CCC) with 95% confidence intervals (CIs), and Bland-Altman (BA) methods.
RESULTS: Mean age was 79 years, and mean LVEF was 44%±11% by CMR and 54%±16% by echocardiography. Inter-observer reproducibility of echocardiographic visual categorical grading by expert readers was poor, with a CCC of 0.475 (-0.7, 0.74). Echocardiographic Doppler regurgitant fraction reproducibility was modest (CCC 0.59, 0.15-0.84; BA mean difference -3.7%, -38% to 31%). CMR regurgitant fraction reproducibility was excellent (CCC 0.95, 0.86-0.98; BA mean difference -2.4%, -11.9 to 7.0), with a lower mean difference and narrower limits of agreement compared to echocardiography. Categorical severity grading by CMR using published ranges had good inter-observer agreement (CCC 0.86, 0.62-0.95).
CONCLUSIONS: CMR performs very well in the quantitation of MR after MitraClip insertion, with excellent reproducibility compared to echocardiographic methods. CMR is a useful technique for the comprehensive evaluation of residual regurgitation in patients after MitraClip. Technical limitations exist for both techniques, and quantitation remains a challenge in some patients.

Entities:  

Keywords:  MitraClip; Mitral regurgitation (MR); cardiac magnetic resonance (CMR)

Year:  2015        PMID: 26309843      PMCID: PMC4526498          DOI: 10.3978/j.issn.2225-319X.2015.05.03

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN: 2225-319X


  33 in total

1.  Quantification of regurgitant fraction in mitral regurgitation by cardiovascular magnetic resonance: comparison of techniques.

Authors:  Mark W S Kon; Saul G Myerson; Neil E Moat; Dudley J Pennell
Journal:  J Heart Valve Dis       Date:  2004-07

2.  Quantitative assessment of severity of mitral regurgitation by serial echocardiography in a multicenter clinical trial of percutaneous mitral valve repair.

Authors:  Elyse Foster; Hal S Wasserman; William Gray; Shunichi Homma; Marco R Di Tullio; Leonardo Rodriguez; William J Stewart; Patrick Whitlow; Peter Block; Randy Martin; John Merlino; Howard C Herrmann; Susan E Wiegers; Frank E Silvestry; Andrew Hamilton; Alan Zunamon; Kimberly Kraybill; Ivor L Gerber; Sarah G Weeks; Yan Zhang; Ted Feldman
Journal:  Am J Cardiol       Date:  2007-11-15       Impact factor: 2.778

Review 3.  Cardiovascular magnetic resonance imaging for valvular heart disease: technique and validation.

Authors:  Peter J Cawley; Jeffrey H Maki; Catherine M Otto
Journal:  Circulation       Date:  2009-01-27       Impact factor: 29.690

4.  Evaluation of aortic regurgitation by cardiac cine magnetic resonance imaging: planar analysis and comparison to Doppler echocardiography.

Authors:  G Aurigemma; N Reichek; M Schiebler; L Axel
Journal:  Cardiology       Date:  1991       Impact factor: 1.869

5.  Calculations of cardiovascular shunts and regurgitation using magnetic resonance ventricular volume and aortic and pulmonary flow measurements.

Authors:  Daniel G H Devos; Philip J Kilner
Journal:  Eur Radiol       Date:  2009-08-29       Impact factor: 5.315

Review 6.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

7.  Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study.

Authors:  Patrick L Whitlow; Ted Feldman; Wes R Pedersen; D Scott Lim; Robert Kipperman; Richard Smalling; Tanvir Bajwa; Howard C Herrmann; John Lasala; James T Maddux; Murat Tuzcu; Samir Kapadia; Alfredo Trento; Robert J Siegel; Elyse Foster; Donald Glower; Laura Mauri; Saibal Kar
Journal:  J Am Coll Cardiol       Date:  2012-01-10       Impact factor: 24.094

8.  Residual mitral valve regurgitation after percutaneous mitral valve repair with the MitraClip® system is a risk factor for adverse one-year outcome.

Authors:  Liliya Paranskaya; Giuseppe D'Ancona; Ilkay Bozdag-Turan; Ibrahim Akin; Stephan Kische; Gökmen R Turan; Tim Rehders; Jasmin Ortak; Christoph A Nienaber; Hüseyin Ince
Journal:  Catheter Cardiovasc Interv       Date:  2013-02-12       Impact factor: 2.692

9.  Quantitative Doppler assessment of valvular regurgitation.

Authors:  M Enriquez-Sarano; K R Bailey; J B Seward; A J Tajik; M J Krohn; J M Mays
Journal:  Circulation       Date:  1993-03       Impact factor: 29.690

Review 10.  Heart valve disease: investigation by cardiovascular magnetic resonance.

Authors:  Saul G Myerson
Journal:  J Cardiovasc Magn Reson       Date:  2012-01-19       Impact factor: 5.364

View more
  5 in total

Review 1.  Echocardiographic evaluation and guidance for MitraClip procedure.

Authors:  William E Katz; Anson J Conrad Smith; Frederick W Crock; João L Cavalcante
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

2.  Initial Slovenian experience with MitraClip therapy : Careful selection of patients is crucial for optimal outcome.

Authors:  Jana Ambrožič; Marta Cvijič; Mojca Bervar; Špela Mušič; Matjaž Bunc
Journal:  Wien Klin Wochenschr       Date:  2017-12-04       Impact factor: 1.704

3.  3D vena contracta area after MitraClip© procedure: precise quantification of residual mitral regurgitation and identification of prognostic information.

Authors:  Alexander Dietl; Christine Prieschenk; Franziska Eckert; Christoph Birner; Andreas Luchner; Lars S Maier; Stefan Buchner
Journal:  Cardiovasc Ultrasound       Date:  2018-01-09       Impact factor: 2.062

4.  Direct measurement of atrioventricular valve regurgitant jets using 4D flow cardiovascular magnetic resonance is accurate and reliable for children with congenital heart disease: a retrospective cohort study.

Authors:  Kimberley Jacobs; Joseph Rigdon; Frandics Chan; Joseph Y Cheng; Marcus T Alley; Shreyas Vasanawala; Shiraz A Maskatia
Journal:  J Cardiovasc Magn Reson       Date:  2020-05-14       Impact factor: 5.364

5.  Invasive hemodynamics are equivocal for functional outcomes after MitraClip.

Authors:  Juliette E Power; Chris Reiff; Adamantios Tsangaris; Alexandra Hall; Ganesh Raveendran; Demetris Yannopoulos; Sergey Gurevich
Journal:  Health Sci Rep       Date:  2022-01-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.